An adjuvant autologous therapeutic vaccine %252528HSPPC-96%2…
An adjuvant autologous therapeutic vaccine %252528HSPPC-96%25253B vitespen%252529 versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma%25253A a multicentre%25252C open-label%25252C randomised phase III trial.
Article, Chapter
Full text availability for this item
Journal:
Lancet, TheOpens in new Window
Coverage:
- 1823-10-05~present; volume:1~present;issue:1~present